WeightWatchers is buying digital health company Sequence to capitalize on the hot market for diabetes and weight loss drugs including Ozempic and Wegovy. WSJ's Andrea Petersen explains what this could mean for the wellness industry.
Further Reading:
-WeightWatchers Moves Into the Ozempic Market With Telehealth Deal
-How a Diabetes Drug Became the Talk of Hollywood, Tech and the Hamptons
-Health Startups Offer Diabetes Drugs Like Ozempic for Weight Loss With Little Oversight
Learn more about your ad choices. Visit megaphone.fm/adchoices
Podden och tillhörande omslagsbild på den här sidan tillhör The Wall Street Journal & Gimlet. Innehållet i podden är skapat av The Wall Street Journal & Gimlet och inte av, eller tillsammans med, Poddtoppen.
